Overview

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

To compare efficacy and safety of Abivertinib maleate alone versus standard first-line EGFR-TKIs for the treatment of patients with advanced non-small cell lung cancer with sensitive EGFR mutation

Phase:

Phase 3

Details

Lead Sponsor:

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Collaborator:

Guangdong Provincial People's Hospital

Treatments:

Abivertinib
Gefitinib
Maleic acid